摘要
目的评价血清CA19-9、CEA及粪便K—ras12基因突变在胰腺癌诊断中的价值。方法对38例胰腺癌和175例胰腺良性疾病患者的血清CA19—9、CEA、粪便K—ras12基因突变结果进行ROC曲线分析。结果血清CA19—9、CEA、粪便K—ras12基因突变单一指标诊断胰腺癌的敏感度分别为73_7％、658％、78．9％，特异度分别为77．1％、811％、89．7％，ROC曲线下面积分别为0．784、0．709、0．843，三个指标联合检测（平行试验）诊断胰腺癌的敏感度为97．4％、特异度为60．6％，ROC曲线下面积为0．902。结论血清CA19—9、CEA、粪便K—ras12基因突变三个指标的联合检测可显著提高诊断胰腺癌的敏感性。
Objective To evaluate the application of serum CA19-9, CEA levels and K-ras12 gene mutation in stool in diagnosis of pancreatic cancer. Methods Serum CA19-9, CEA levels and fecal K-ras12 gene mutation were detected in 38 patients with pancreatic cancer and 175 patients with benign pancreatic diseases; the results were analyzed by ROC curve. Results The Sensitivity, specificity and area under ROC curve （AUC） of single test of serum CA19-9, CEA and fecal K-ras12 mutation for the diagnosis of pancreatic carcinoma were 73.7%, 65.8%, 78.9%; 77.1%, 81.1%, 89.7%; 0.784,0.709, 0.843 respectively; those for the combined detection （parallel test） of three markers were 97.4%, 60.6% and 0.902, respectively. Conclusion Combined detection of serum CA19-9,CEA and fecal K-ras12 gene mutation can improve diagnostic sensitivity for pancreatic cancer.
出处
《浙江医学》
CAS
2012年第18期1494-1496,共3页
Zhejiang Medical Journal
基金
金华市科技局技术创新资助课题（2007-3-008）
